Stage III Non-Small Cell Lung Cancer represents one of the most heterogenous subgroups of lung cancer. The choice of multimodality treatment including chemotherapy, surgery, immunotherapy and radiotherapy within this subgroup of lung cancer, varies significantly among clinicians. In this session I would address the management of Stage III NSCLC based on published evidence and international guidelines.